ESMO 2022 | DURIGAST: 2L FOLFIRI plus durvalumab plus tremelimumab in GC or GE junction adenocarcinoma

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, provides an overview of the Phase II PRODIGE 59-DURIGAST (NCT03959293) trial investigating FOLFIRI with durvalumab with or without tremelimumab in the second-line of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. The primary endpoint was progression-free survival (PFS) at 4 months and secondary outcomes was overall-survival (OS). The primary endpoint was not met in either month, however, PFS was 5 months and OS was almost 1 year. These results are better than chemotherapy alone, suggesting FOLFIRI with two immune checkpoint inhibitors should be evaluated in the second-line setting. Biomarker analysis is ongoing to evaluate the 20-30% of patients with good response to the combination of FOLFIRI plus durvalumab with tremelimumab. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.